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Abstract
The present document describes the SIUMB (Italian Society of Ultrasound in Medicine and Biology) guidelines for the use of 
ultrasound in the management of focal liver disease. The aim of the paper is to provide a clinical practice guideline for Italian 
physicians who are approaching the ultrasound study of a focal liver lesion. In particular, these guidelines provide simple 
indications, recommendations and general practice advices for the correct use of contrast-enhanced ultrasound (CEUS) in 
this scenario. They represent the SIUMB position of the ultrasound role in the diagnostic flow charts of the principal focal 
liver lesions, and are in agreement with other, previously published national and international guidelines.
Keywords Contrast enhanced ultrasound · Hepatocellular carcinoma · Cholangiocellular carcinoma · Metastasis · Focal 
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Preamble
This document represents the results of the Italian Society 
of Ultrasound in Medicine and Biology (SIUMB) guideline 
committee’s research concerning the use of conventional and 
contrast enhancement ultrasound in focal liver disease. In 
2016, we started collecting data from literature (guidelines, 
scientific papers, and expert opinions) published over the 
past 10 years about the role of contrast-enhanced ultrasound 
(CEUS) in focal liver disease. Recommendations were for-
mulated on the basis of the data analyzed. They were then 
evaluated by a panel of Italian physicians, experts in the use 
of ultrasound in focal liver disease. This “Consensus” was 
held in Rome, on 20 November 2017, during the last national 
conference. The results of the expert committee’s work were 
presented to SIUMB members on 21 November 2017, and 
the text, including recommendations, was then approved 
by the SIUMB executive bureau on 20 January 2018. This 
document is the summary of the SIUMB’s position regard-
ing the use of contrast-enhanced ultrasound in focal liver 
disease. It aims to be a guideline to define the situations 
which are appropriate to propose a more sophisticated ultra-
sound imaging technique, such as contrast-enhanced ultra-
sound (CEUS), and when other imaging techniques need to 
be used.
Motivations and methodology of the SIUMB 
guidelines concerning the use of ultrasound 
in focal liver lesions
The importance of ultrasound, and in particular the use of 
ultrasound contrast agents (UCAs), is well recognized in 
Italy, but we missed a guideline document developed by 
SIUMB. In the light of this lack, and on the strength of two 
decades’ experience using contrast-enhanced ultrasound, 
SIUMB set up a guidelines committee.
In the first meeting, held in Rome in September 2016, 
the authors carried out an analysis and selection of the 
already-published guidelines concerning the contributions 
of unenhanced and enhanced ultrasound to the diagnosis of 
focal liver lesions. The European Federation of Societies 
for Ultrasound in Medicine and Biology ( EFSUMB) guide-
lines, published for the first time in 2004, and updated in 
2008, and the World Federation For Ultrasound in Medicine 
and Biology (WFUMB)–EFSUMB guidelines, in particular, 
were evaluated. The latter, published in 2013, represent the 
worldwide guidelines (published in Ultrasound in Medicine 
and Biology and in Ultraschall in der Medizin/European 
Journal of Ultrasound) [1–3]. All these documents show a 
deep analysis of the use of UCAs and its role and pattern in 
the characterization of each of the focal liver lesions.
After this analysis, we moved to evaluate the liver appli-
cations of CEUS in clinical scenarios, and its recognized 
role in the fields of hepatology and gastroenterology. This 
was a hot topic for Italian physicians, especially in the period 
between 2010 and 2013, because of the American Associa-
tion for the Study of Liver Diseases (AASLD) decision not 
to consider the use of CEUS in the diagnostic flow chart of 
a new nodule developed in patients with chronic hepatitis 
or cirrhosis, after its role had already been recognized in 
previous guidelines published by the same society in 2005 
[4, 5]. The reasons the AASLD gave for removing CEUS 
from the diagnostic flow chart of HCC were the possibility 
to misdiagnose cases of intrahepatic cholangiocarcinoma, 
although is very rare in cirrhotic liver (about 1–3%), and 
also the poor availability of such a diagnostic method in 
the United States of America [6]. The AASLD document 
was counterbalanced by a position paper developed by the 
Italian Association for the Study of the Liver (AISF) and 
published in 2013, in which CEUS was identified as a useful 
imaging modality in the diagnostic work-up of a new nodule 
developed in a cirrhotic liver [7]. This paper allowed Ital-
ian hepatologists to overcome the limit on the use of CEUS 
introduced in the AASLD guidelines published in 2010 and 
updated in 2011 [4, 5]. It happened after that, in previous 
years, other international societies had already adopted the 
use of contrast-enhanced ultrasound in hepatological clini-
cal practice [8].
The American College of Gastroenterology (ACG) clini-
cal guideline concerning the diagnosis and management of 
focal liver lesions, published in 2014, presented CEUS as 
an emerging modality that had some utility, especially in 
the diagnosis of benign lesions like hemangioma and focal 
nodular hyperplasia (FNH), but was not widely available in 
the United States. For this reason, the authors preferred to 
focus their attention on contrast-enhanced computed tomog-
raphy (CECT) and contrast-enhanced magnetic resonance 
imaging (CEMRI) [9].
Finally, we evaluated two additional guideline documents. 
The first, published by the European Association For the 
Study of the Liver–European Organization for Research and 
Treatment of Cancer (EASL–EORTC) in 2012, which con-
cerned the management of hepatocellular carcinoma, did not 
include any indications for the use of CEUS. The second, 
the European Association for the Study of the Liver (EASL) 
clinical practice guidelines on the management of benign 
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liver tumors, published in 2016, acknowledged CEUS a 
diagnostic role in all benign lesions except for adenoma 
[10, 11].
To be complete and comprehensive, we evaluated two 
other documents after analyzing the international guidelines. 
These two documents were written in Italian. The first was 
published by the Ministry of Health in September 2008, as 
part of our national system of guidelines (SNLG). It was 
the first Italian document concerning the use of imaging 
in the diagnosis of focal liver disease [12]. The latter was 
the joint product of a number of different Italian scientific 
societies, namely: the Italian Association for the Study of the 
Liver Diseases (AISF); the Italian Association of Medical 
Oncology (AIOM); the Italian–International Hepato-Pan-
creato Biliary Association (IT-IHPBA); the Italian Soci-
ety of Surgeons (SIC); the Italian Society of Medical and 
Interventional Radiology; and the Italian Society of Organs 
Transplantation (SITO), which wrote a document, published 
online in 2016, that included recommendations for the man-
agement of patients with hepatocellular carcinoma [13].
After the analysis of international and national guide-
lines, the second step was to evaluate the most important 
papers on the role of conventional and contrast-enhanced 
ultrasound in the management of patients with focal liver 
lesions. To do that, we carried out a bibliographic search by 
entering the following terms in PubMed: “liver cancers and 
ultrasound and contrast enhanced ultrasound.” The research 
was limited to the period between 2006 and 2016, and led 
to the identification of 899 articles. By activating filters for 
clinical trials, review and meta-analyses, we reduced these 
to 77 clinical trials, 132 reviews, 11 systematic reviews, and 
4 meta-analyses [14–17]. We proceeded to filter these docu-
ments, only including: studies conducted on humans; studies 
in which the use of CEUS has been evaluated in terms of the 
identification and characterization of liver lesions, and the 
reporting data in terms of sensitivity/specificity or positive 
and negative predictive value (VPP-VPN); studies in which 
Sonovue (Bracco, Italy) was the only ultrasound contrast 
agent employed (we have excluded data related to the use 
of Sonazoid and Definity, because at the moment they are 
not available in our country); studies in which a qualitative 
evaluation of contrast medium has been performed (we have 
excluded studies in which quantitative assessments have 
been made with wash in/wash out time intensity curves, 
with or analysis of images using software such as Photo-
shop, etc.); studies in which there were at least 30 patients 
(with at least 10 benign liver lesions and 10 malign hepatic 
lesions); studies published in English; and studies in which 
the gold standard was the histological result, the CT and/or 
MRI diagnosis, or the clinical and radiological follow-up. 
In this first document, the SIUMB’s guidelines committee 
decided to focus mainly on the ultrasound diagnostic aspects 
of focal liver lesions, with no recommendations regarding 
the evaluation of tumor response after loco-regional treat-
ment and systemic therapy. This topic will be addressed in 
a later document.
In drafting the final document, we decided to report the 
conclusions of the existing literature as recommendations, 
and to include the experts’ opinions on all the focal liver 
lesions presented.
The evidence for and strength of the recommendations 
were assessed according to the Grading of Recommenda-
tions Assessment, Development, and Evaluation (GRADE) 
system [18]. The strength of recommendations depends 
on the quality of the evidence. Each recommendation was 
graded as strong or weak. High-quality evidence corre-
sponded to a strong recommendation, while a lack of or 
uncertain evidence resulted in a weaker recommendation.
The SIUMB’s experts committee voted on each of the 
statements. Each member of the committee had the ability 
to approve, disapprove or abstain from voting on a particular 
statement. A strong consensus was reached when there was 
agreement in > 95%, while broad consensus was achieved 
when > 80% of the experts agreed.
General considerations 
about ultrasonography in focal liver lesions
Introduction
Ultrasonography is usually the first imaging technique 
adopted by clinicians to study the liver. Its widespread use 
brought great advances in clinical hepatology. Before the 
advent of ultrasound and other imaging modalities like CT 
or MRI, it was almost impossible to discover focal liver 
lesions in asymptomatic patients, and the natural history 
of liver tumors was almost unknown to clinicians. Real-
time ultrasonography is the most frequently used imaging 
procedure for primary diagnosis of focal liver lesions and 
in the survey of patients affected by chronic liver diseases 
and tumors of the gastrointestinal tract [19]. The evaluation 
of liver lesions has taken on great importance because of 
the increasing incidence of primary hepatic malignancies, 
especially hepatocellular carcinoma (HCC) and cholangio-
carcinoma. In this arena, the first task of an ultrasound is to 
detect a focal liver mass, while the second is (possibly) to 
characterize it.
Generally, detection is made via B-mode ultrasound. In 
most cases, it is not possible to characterize and differenti-
ate benign from malignant lesions using this mode, since it 
lacks specificity in characterizing focal liver lesions [20]. 
The characterization is a process that requires other tech-
nologies able to help a clinician in evaluating the vascular 
supply of the tumors. In the liver, such tumors are mostly 
hypervascular. In this sense, the advent of Doppler was an 
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improvement. That technology made it possible to display 
the vascular abnormalities of a liver mass, but the avail-
ability of blood pool contrast agents for ultrasound, together 
with the development of harmonic imaging, has opened up 
new possibilities, both for the immediate characterization of 
any lesion detected in the liver, and for increasing the sensi-
tivity of ultrasonography in the detection of liver metasteses 
[19–22].
Ultrasound contrast agents and contrast‑specific 
modes
The unique ultrasound contrast agent licensed in Italy and 
in Europe is Sonovue (Bracco, Milan, Italy). It consists of 
bubbles that have a flexible shell, allowing them to oscil-
late when insonated at a low mechanical index (MI). MI is 
a parameter that measures the acoustic power of the ultra-
sound beam and determines the harmonic echo frequencies, 
coming from the resonating bubbles, which can be con-
stantly imaged in real time. The low mechanical index imag-
ing technique has become the method of choice adopted by 
all the companies which produced ultrasound scanners. This 
method avoids the destruction of the bubbles and provides 
continuous dynamic imaging, which allows for the assess-
ment of the arterial inflow, capillary distribution and venous 
outflow within a parenchymal organ. In turn, this enables the 
study of both macro- and microcirculation. Indeed, the size 
of the microbubbles allows free passage through the capillar-
ies. Sonovue is distributed within the whole blood volume, 
but does not diffuse into the extracellular fluid space. A low 
mechanical index imaging technique using a second-gener-
ation ultrasound contrast agent has become the method of 
choice for the detection and characterization of focal liver 
lesions. The signal coming from the bubbles is detected by 
contrast-specific US modes, which work by erasing the lin-
ear ultrasound signal coming from the tissue and using the 
nonlinear responses from microbubbles to form images [2]. 
Each manufacturer has developed its own specific contrast 
mode, which effectively allows for tissue cancelation to gen-
erate almost pure microbubble images.
Administration and dosing
Sonovue is administered by an intravenous bolus injection 
(preferably into an antecubital fossa vein), followed by a 
flush saline solution to push the agent into the central venous 
stream. The recommended dose for a single injection is half 
a vial, which amounts to 2.0–2.5 ml. However, the optimal 
dose for a particular clinical situation depends on the scanner 
technology used, and should be adjusted accordingly. The 
intravenous cannula should be at least 20 G in caliber, and 
the syringe should be connected directly or via the straight 
line of a T-connector. In this way, it is possible to avoid 
excessive mechanical stress during injection and prevent the 
destruction of the stable microbubbles [23].
Safety of ultrasound contrast agents
UCAs are safe, with very rare side effects and an excel-
lent tolerance in clinical practice. The incidence of severe 
hypersensitivity event is lower than that for CT contrast 
agents, and is comparable to that of MRIs. In abdominal 
applications, the incidence of life-threatening anaphylactoid 
reactions is 0.0001%, with no deaths in a series of > 23,000 
patients [24]. Ultrasound contrast agents are not nephrotoxic, 
cardiotoxic or hepatoxic. Therefore, it is not necessary to 
perform renal function tests before doing them.
Although there is a theoretical possibility that the inter-
action of diagnostic ultrasound and UCA could produce 
bioeffects, there is no clinical evidence for adverse effects 
on human liver. For safety reasons, and to align with other 
guidelines, the SIUMB’s recommendations are:
– to ensure every patient provides informed, written con-
sent before an examination is done;
– to work in a laboratory in which there are resuscitation 
facilities;
– to be careful with patients with a history of severe coro-
nary disease; and
– to avoid using ultrasound contrast agents for 24 h before 
extracorporeal shockwave therapy.
Examination technique and principle concepts 
in the interpretation of the images
Generally, contrast-enhanced ultrasound (CEUS) is per-
formed after a gray-scale B-mode ultrasound, which repre-
sents the first step of the examination. It should be kept in 
mind that if the baseline ultrasound is suboptimal, CEUS 
may be unsatisfactory [3]. For best results, it is important 
to perform a high-quality un-enhanced ultrasound exami-
nation using tissue harmonic imaging and vascular Dop-
pler technologies, to detect focal liver lesions and to find 
the best scan for the subsequent study with CEUS. Very 
small focal liver lesions, especially those located at the 
dome of the liver in sub-diaphragmatic segments, which 
occur mainly in patients affected by steatosis, may be dif-
ficult to identify in B-mode ultrasound, as well as with 
CEUS [3]. For these cases, we suggest intercostal scan-
ning and positioning the patient in the left decubitus to 
improve the acoustic window. After the evaluation of the 
target mass, the next step is to move to contrast mode, 
maintaining the best detection scan. This switching causes 
the US scanner screen to split into two parts, one of which 
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will be focused on the detection of the signal coming from 
the bubbles, while the other will be focused on the signal 
coming from the tissue. Some scanners allow for the pos-
sibility of merging both signals in a mixing mode with 
different colors. During contrast mode, which is an imag-
ing modality with a low MI, the signal coming from the 
tissue is very useful and allows to for a guided scan that 
facilitates the characterization of the target.
The liver has a double blood supply, which consists 
of an arterial and a portal flow. 70% of the blood sup-
port arrives through the portal vein, while the remainder 
arrives via the hepatic artery. Considering that micro-
bubbles trespass the capillary bed, we have to follow the 
dynamic change of the enhancement during the arterial, 
portal and parenchymal, or late, phase (Table 1). The arte-
rial phase generally starts within 20 s after the injection 
of the contrast and lasts for 30–45 s, though the beginning 
depends on the circulatory status of the patient. The portal 
venous phase starts after 30–45 s and usually lasts until 
the 2-min mark, while the parenchymal phase starts after 
2 min and is limited to 4–6 min.
The appearance of a lesion during the contrast mode 
should be described in terms of degree of the enhancement 
in all the phases. The term “enhancement” corresponds to 
the grade of perfusion with respect to the rest of the liver 
parenchyma. In this way, we can distinguish four perfusion 
patterns, which are, respectively, called hyperenhancement 
if there is hyperperfusion, hypoenhancement if the lesion 
is hypoperfused, and isoenhancement if it shows the same 
perfusion of the rest of the liver. Finally there are also 
not perfused lesions, in which there is no enhancement 
because there are no vessels inside.
The arterial phase is useful in the evaluation of the 
behaviors of the vascular arterial supply. In particular, it 
allows to focus on the type and timing of the filling (cen-
tripetal or centrifugal). Portal and late phases are more 
important, because in these phases, we can determine if 
the lesion is benign or malignant. A lesion that shows a 
decrease in the enhancement with a hypovascular aspect is 
typically malignant; while, if the lesions are iso- or hyper-
enhancing in the portal or late phases, they are typically 
benign. According to the literature, the smallest lesions 
that are detectable with CEUS range between 3 and 5 mm 
in diameter [25].
Ultrasound aspects of focal liver 
lesions: un‑enhanced and enhanced 
ultrasonography
Introduction and clinical approach to the study 
of focal liver lesions
Before performing an ultrasound examination (B-mode 
and/or CEUS), it is also important to take the time to col-
lect information concerning the clinical aspects of the 
patient’s life. This can help to produce a better diagnostic 
outcome. First of all, it is important to consider the age 
and the sex of the patient. In fact, the probability of finding 
a malignant lesion in a young person is lower than in an 
older patient. At the same time, the probability that par-
ticular kinds of focal liver lesions, like FNH or HCA, will 
be detected is higher in female patients. Another important 
issue is to know the clinical history of the patient. We can 
distinguish between three general scenarios:
– healthy patients with no history of cancer;
– patients with a history of cancer; and
– patients with a history of chronic hepatitis or cirrhosis.
Being aware of the clinical background can help us 
to better understand and forecast the type of lesion we 
are studying. For instance, oral contraceptive use in the 
absence of underlying liver disease could be suggestive 
of hepatocellular adenoma, while a new lesion identified 
in a patient with chronic hepatitis could be highly sugges-
tive of HCC. The detection of a new lesion in a patient 
with a previous history of tumors could be suggestive of a 
secondary liver lesion.
Ultrasound behaviours of different focal liver 
lesions: the results of the SIUMB expert committee
The following paragraphs describes the ultrasound aspects 
of focal liver lesions, putting in evidence unenhanced and 
enhanced ultrasound behaviors. Rare tumors are not dis-
cussed in this document, because at the moment there is 
not enough evidence for their detection with CEUS. There 
also indications and recommendations about following 
diagnostic flow charts in those cases in which ultrasound 
is not able to characterize a focal liver lesion. All the state-
ments that follow represent a summary of the discussion 
which occurred during the SIUMB’s experts’ committee 
Table 1  Contrast phases of the liver
Phase Start (s) End (s)
Arterial 10–20 25–35
Portal-venous phase 30–45 120
Late phase > 120 Bubble 
disap-
pearance
(4–6 min)
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meeting, and constitute the Italian guidelines for approach-
ing the study of a focal liver lesion.
Benign focal liver lesions
The benign focal liver lesions discussed in the following 
paragraphs are hepatic cyst, hydatid cyst, hemangioma, 
focal nodular hyperplasia, and adenoma. Focal fatty 
change was not considered properly a lesion, even though 
it can look like a mass, especially when hypoechoic and 
located in unusual sites. As an area of focal fatty infil-
tration or fatty sparing, it does not differ in vasculature 
from the surrounding liver tissue. In a contrast-enhanced 
ultrasound, it shows the same enhancement pattern as 
adjacent liver parenchyma in all the phases. Regenerative 
nodules are benign lesions developed in patients with cir-
rhosis, which generally show the same enhancement of the 
surrounding liver tissue, even though during the arterial 
phase, it could be possible to find a hypoenhanced aspect. 
The most important behavior of all the benign lesions in 
CEUS is that all of them show sustained enhancement in 
the portal and late phases. Their characterization depends 
on the type of enhancement during the arterial phase.
Hepatic cyst
Ultrasonography is highly accurate in the characterization 
of simple hepatic cysts, especially when typical features are 
present (anechoic appearance, thin walls, posterior acoustic 
enhancement and lateral acoustic shadows). Its sensitivity 
and specificity rates are higher than 90% [9, 10]. A sim-
ple, asymptomatic cyst should be managed conservatively 
(strong recommendation, moderate grade of evidence). 
Cystic lesions characterized by multiple and/or thick septa, 
wall irregularities, solid papillary projections, calcifications 
and/or daughter cysts should be investigated with color Dop-
pler evaluation and contrast-enhanced imaging modalities. 
After CEUS, simple cysts (or those complicated by hemor-
rhage or infection) show no vascularization of contents and 
walls in all the vascular phases (strong recommendations, 
low grade of evidence). Strong consensus (35 approved/0 
disapproved/0 abstained. 100%).
Parasitic cyst
The sensitivity of ultrasound for evaluation of Echinococ-
cus is 90–95% [26]. The ultrasound behavior of this cyst 
depends on its evolutionary phase. At the beginning, it could 
appear as an anechoic, smooth, or round cyst, any of which 
can be difficult to distinguish from a benign cyst. With pro-
gression, the lesion may develop a thick and often calcified 
wall. Characteristic internal septa can be seen in the pres-
ence of daughter cysts. Ultrasound allows for a classification 
system that includes six classes (CL, CE 1,CE 2, CE 3, CE 
4, and CE 5) divided into four groups (liquid cysts, activate 
parasitic cysts, transitional cysts, and inactive cysts) that cor-
respond to the pathophysiology of the growth of the parasite 
[27]. The ultrasound behaviors of each class are reported 
in Table 2. The diagnosis of Echinococcus cysts requires 
the integration of ultrasound findings with serological tests, 
second-level imaging and the possible ultrasound-guided 
aspiration puncture of the endocystic fluid (strong recom-
mendation, high grade of evidence). Strong consensus (35 
approved/0 disapproved/0 abstained. 100%).
Hepatic abscess
Hepatic abscesses can appear in ultrasound as hypoechoic 
or hyperchoic lesions, depending on their size and the evo-
lutionary status. Generally, however, they occur as hypo-
echoic lesions, with irregular walls and variable content 
Table 2  Ultrasound behaviors of hydatid cysts
Type of cyst Biological activity Ultrasound features
CL Undetermined Cyst lesion (CL) with an anechoic content, in which the typical parasitic cyst wall is not detectable. This 
aspect could be present at the beginning of the infection by Echinococcus Granulosus. These ultrasound 
findings alone do not allow to perform the diagnosis of a parasitic cyst
CE-1 Active Cyst lesion (CL) with an anechoic content, in which the typical cyst wall is detectable and the content could 
be characterized by echoes called hydatid sand
CE-2 Active Multilocular cysts with septa, in which the typical cyst wall is visible
CE-3 Transitional Cyst lesions, characterized by anechoic aspect and floating membranes, due to the separation of the lami-
nated membranes from the cyst wall. These internal arrangements could modify the shape of the cyst by 
the decreasing of the internal pressure. In this stage the cyst could degenerate more or give daughter cysts. 
These ultrasound findings alone do not allow to perform the diagnosis of a parasitic cyst
CE-4 Inactive Cyst with degenerative contents (hypoechoic or hyperechoic material). No daughter cysts inside
CE-5 Inactive Calcified cysts with the involvement of the entire wall or part of it. These ultrasound findings alone do not 
allow to perform the diagnosis of a parasitic cyst
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(solid material and or gas) [28]. Their contrast-enhanced 
ultrasound behaviors depend on the state of the inflamma-
tion, which is an evolving process, and which progresses 
until liquefaction in mature abscesses [29]. The diagnosis of 
such abscesses is made by association between clinical signs 
and ultrasound imaging findings. In CEUS, abscesses show 
a peripheral rim enhancement during the arterial phase. This 
can persist in the portal phase, but usually decreases in the 
parenchymal phase. There is a lack of enhancement in the 
center of the lesion due to liquefaction. This pattern could 
be also observed in patients with infected granulomatous 
lesions. Ultrasound-guided puncture is useful for the char-
acterization of the abscess, microbiological tests, and local 
treatment, that is, aspiration/drainage positioning. (Strong 
recommendations, moderate grade of evidence). Strong 
consensus (35 approved/0 disapproved/0 abstained. 100%).
Hepatic hemangioma
The typical ultrasound appearance of hepatic hemangioma 
is as a hyperechoic lesion with well-defined margins, but 
sometimes its aspect can be hypoechoic or inhomogene-
ous creating diagnostic doubts, especially in patients with 
oncological history or affected by chronic liver disease. 
The advent of contrast-enhanced ultrasound (CEUS) has 
improved both the sensitivity and specificity of US, reaching 
a high level of accuracy in the non-invasive diagnosis of the 
condition [9, 10, 30–32]. A hyperechoic lesion smaller than 
3 cm (round shape, without a “halo sign” and with regular 
margins), detected in patients with normal liver ultrasound 
features and in the absence of a history of oncological dis-
ease, is probably a hemangioma and B mode ultrasound is 
sufficient for the diagnosis. In patients with hepatic steatosis, 
hemangioma may show an atypical hypoechoic appearance. 
In the presence of a large lesion, meanwhile, the ultrasound 
echostructure can be heterogeneous. Doppler evaluation is 
not useful for the diagnosis [10]. Typical hepatic hemangio-
mas with diameters < 3 cm do not require follow-up. When 
hemangioma is suspected, detected in patients with a his-
tory of cancer or affected by chronic liver disease, or when 
the lesion is bigger than 3 cm or shows atypical ultrasound 
features, it must be characterized with second-level imaging 
modalities, such as CEUS, CECT or CEMRI. The diagnosis 
of hemangioma with contrast-enhanced ultrasound is based 
on the typical peripheral globular enhancement pattern in 
the arterial phase, followed by centripetal filling in the portal 
and late phases [2, 3]. (Strong recommendations, moderate 
grade of evidence.) Strong consensus (35 approved/0 disap-
proved/0 abstained. 100%).
Focal nodular hyperplasia
The B-mode ultrasound behaviors of FNH are variable, 
but it is usually slightly hypoechoic or isoechoic, and very 
rarely hyperchoic. The central scar is visible on ultrasound in 
20–30% of cases. After color Doppler evaluation, the lesion 
is hypervascularized, with hypertrophic vascular arteries 
that have the appearance of a spoked wheel. The lesion 
is characterized by vessels that rise from the center to the 
periphery of the nodule. Spectral Doppler analysis shows an 
arterial flow with a low resistive index.
When there are typical vascular characteristics, CEUS, 
CECT and CEMRI are able to reach a specificity level very 
close to 100%. In contrast-enhanced ultrasound, this lesion 
shows a rapid filling, starting from the center and moving 
out to the borders, with a centrifugal progression. In the 
arterial phase, it can take on a hypervascular aspect that 
can be maintained in all the phases, or it can show an iso-
vascular appearance in the portal or late phase, comparable 
to that of hepatic parenchyma [9, 10, 32–36]. In the portal 
and late phases, the central scar, which has a hypovascular 
appearance, can be highlighted [37]. CEMRI shows a higher 
diagnostic accuracy rate for FNH. FNH does not typically 
require instrumental follow-up, except when it is associated 
with vascular malformative diseases [10]. (Strong recom-
mendations, high grade of evidence.) Strong consensus (35 
approved/0 disapproved/0 abstained. 100%).
Hepatic adenoma
The ultrasound aspect of the adenoma is variable and is con-
ditioned by size, necrotic hemorrhagic evolution, and adi-
pose content. Although study with color Doppler can docu-
ment vascular signals, both arterial (with a reduced resistive 
index) and venous (both on the periphery and in the center), 
these aspects are not pathognomonic. CEUS is indicated for 
the differential diagnosis compared to the other focal liver 
lesions, but it is not accurate in confirming the diagnosis of 
adenoma or classifying the subtype [10, 38, 39]. (Strong 
recommendations, low grade of evidence.) Strong consensus 
(35 approved/0 disapproved/0 abstained. 100%).
Rare benign liver tumors
The available data on rare focal liver lesions do not allow for 
the formulation of diagnostic recommendations.
Strong consensus (35 approved/0 disapproved/0 
abstained. 100%).
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Malignant focal liver lesions
The malignant focal liver lesions discussed in the following 
subchapters are hepatocellular carcinoma, cholangiocellular 
carcinoma and metastasis, which represent the most com-
mon malignant masses. This document does not address 
other malignant lesions like lymphoma, epithelioid heman-
gioendothelioma or cystoadenocarcinoma, which are rare, 
and will be discussed elsewhere. Generally, all the malignant 
lesions show a hypoenhanced aspect in contrast-enhanced 
ultrasound during the portal or late phase, and the diagnostic 
accuracy of the method is very high [14–17].
Hepatocellular carcinoma
Ultrasonography is the imaging test universally proposed 
for the early detection of HCC in surveillance programs for 
cirrhotic patients. All patients with cirrhosis in Child–Pugh 
Turcotte (CPT) A or B, and those on the waiting list for 
liver transplantation, must be evaluated with periodic ultra-
sound [7]. The ultrasound surveillance program must also be 
extended to non-cirrhotic patients with chronic HCV infec-
tion or bridging fibrosis (Metavir F3), as well as to those 
patients being treated effectively with new directly active 
antiviral agents (DAA). An ultrasound surveillance program 
must be performed on HBV patients at high or intermediate 
risk. For Caucasian patients, the risk can be stratified accord-
ing to the PAGE-B score, which is based on age, gender 
and platelets [40]. Ultrasonography should be performed 
every 6 months [7]. The examination should be carried 
out by experienced operators in dedicated centers and with 
high-level technological equipment. Each new nodule found 
in cirrhotic patients during a surveillance program, or in 
patients who do not adhere to surveillance programs, must be 
considered a potential HCC nodule. If the nodule is < 1 cm, 
the patient must be enrolled in a surveillance program, with 
ultrasound examinations at intervals of ≤ 4 months. If the 
lesion is ≥ 1 cm, the patient should be investigated with sec-
ond-level imaging techniques [7]. Although conventional 
ultrasound and color Doppler can show suggestive features 
for the diagnosis of HCC (hypoechoic lesions with intra 
and perinodular arterial vascular signals and a high resis-
tive index), the characterization of the nodule must be done 
using contrast-enhanced imaging modalities. CEUS can be 
used for the characterization of nodular lesions in patients 
with chronic liver disease. It allows for the characterization 
of the lesion as HCC when typical contrast enhancement pat-
tern is present. HCC nodules generally show a hypervascular 
aspect during the arterial phase, followed by an isovascular 
and hypovascular aspect during the portal and parenchymal 
phases, respectively [2, 3, 38, 41]. CEUS must be performed 
by experienced operators, and the evaluation of the timing 
and the intensity of the washout is important [42]. In HCC 
nodules, the washout is frequently late (appearing after the 
first 60 s) and not very intense (the lesion does not appear 
markedly hypoechoic after 2–3 min). If the lesion shows 
washout within 60 s and appears markedly hypoechoic in 
portal phase, the possibility of malignant lesions other than 
HCC should be considered [41, 43]. The staging of HCC 
should be done with panoramic imaging modalities like 
CECT and/or CEMRI. CEUS does not have any kind of 
application in this field [7].
If imaging patterns are inconclusive after CEUS and 
CECT or CEMRI, biopsy should be performed. When por-
tal vein thrombosis is present, CEUS allows the clinician to 
characterize the nature of thrombosis (neoplastic vs not neo-
plastic). In the case of neoplastic thrombosis, the thrombus 
appears “hypervascular” in the arterial phase, with washout 
in the portal and late phases. (Strong recommendations, high 
grade of evidence.) Strong consensus (35 approved/0 disap-
proved/0 abstained. 100%).
Cholangiocellular carcinoma
Intrahepatic cholangiocarcinoma (i-CCA) appears in con-
ventional ultrasound as a nodular lesion that if < 3 cm, is 
most often hypoechoic, but the ultrasound aspect is com-
pletely indistinguishable from other liver lesions. The pres-
ence of segmental ectasia in the upstream biliary branches of 
the lesion can be suggestive, but is not specific to the diag-
nosis. Color Doppler has no role in the diagnosis of i-CCA.
In CEUS, the i-CCA behaves like a malignant lesion, 
characterized by a washout in the portal and late phases. 
Generally, the duration of the washout is shorter than that 
of HCC, and starts in the portal phase [41, 44]. The arte-
rial phase is generally characterized by a rim enhancement; 
though it is possible, there will be no enhancement. i-CCA 
can also show a globally hyperenhanced pattern, mainly in 
patients with chronic hepatitis or cirrhosis [45]. The diagno-
sis of i-CCA requires the use of second-level imaging tech-
niques, and biopsy using immunohistochemistry techniques 
should be performed for histologic examination [45–47] 
(Strong recommendations, low grade of evidence.) Strong 
consensus (35 approved/0 disapproved/0 abstained. 100%).
Liver metastasis
The ultrasound aspect of metastatic lesions of the liver 
is variable, and can include any ultrasound appearance. 
Although ultrasound examination is frequently requested 
at the first diagnosis and during follow-up in patients with 
oncological disease, the sensitivity of conventional ultra-
sound in the detection of liver metastases is lower than that 
of second-level imaging techniques (CEUS, CE CT and/or 
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CE MRI). This is particularly true when lesions are < 1 cm. 
Color Doppler US is not indicated for the study of hepatic 
metastases. In CEUS, hepatic metastases are characterized 
by washout in the early portal phase [3]. The accuracy of 
CEUS in the detection of secondary liver lesions is superior 
to that of conventional ultrasound and comparable to that of 
CT and MRI, especially in easily explored patients [14, 20, 
21, 48]. (Strong recommendations, high grade of evidence.) 
Strong consensus (35 approved/0 disapproved/0 abstained. 
100%).
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